Evonetix raises £9m for novel gene synthesis tech – PharmaTimesPharmaTimesCambridge, UK-based Evonetix has raised £9 million to help fuel the advance of its technology designed to enable scalable and high-fidelity gene synthesis. – News – PharmaTimes.a… Continue reading
The Peninsula Qatar |
NCCCR stem cell donor team attends Organ Donor Academy Conference
The Peninsula Qatar Prof Alexander Knuth (left), NCCCR’s Chief Executive Officer and Medical Director, and members of NCCCR’s stem cell donor team at the Doha International Organ Donor Academy Conference. The Peninsula. DOHA: Staff from the stem cell donor team at the … |
Popular Science |
China might be winning the CRISPR race, but we have the FDA
Popular Science But how did China edge out the United States to become the first to use CRISPR in humans? American researchers were, after all, the ones who discovered the techniques’ ability to tweak and alter DNA. But as the Wall Street Journal points out, America … China’s gene editing targets HIV, leukemiaWND.com |
Epidermolysis Bullosa News |
Abeona’s Gene Therapy EB-101 Receives FDA’s Regenerative Medicine Advanced Therapy Designation
Epidermolysis Bullosa News Abeona Therapeutics’ EB-101, a gene therapy in development for patients with recessive dystrophic epidermolysis bullosa (RDEB), has received the regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA … Abeona Gene Therapy Gains FDA Regenerative Medicine DesignationPharmaceutical Processing FDA grants RMAT designation for Abeona’s gene therapy for epidermolysis bullosaEPM Magazine |